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Abstract As replacement of Thr11 of g-conotoxin MVIIC with
Ala significantly reduced the affinity for both N- and P/Q-type
calcium channels, we examined the effect of substitution at this
position with other residues. Binding assays using rat cerebellar
P2 membranes showed that the affinity is in the order of
LeusVal, aminobutyric acid, ThrsAsnESer, Ala, Asp, Phe,
Tyr for N-type channels and ThrsLeu, Val, aminobutyric acid,
Asn, SersAlaEAsp, Phe, Tyr for P/Q-type channels,
suggesting that aliphatic amino acids with longer side chains
are favorable for block of N-type channels. The effects of
substitution were examined electrophysiologically in BHK cells
expressing N-type Ca2+ channels. Inhibition of Ba2+ current by
the analogs did not completely correlate with binding affinity,
although binding to BHK cells was comparable to rat cerebellar
membranes. ß 2001 Federation of European Biochemical So-
cieties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Voltage-sensitive Ca2 channels play important roles in
neuronal activity [1]. They are composed of K1, K2, L, Q,
and N subunits, and the major K1 subunit forms the channel
pore. At least nine types of K1 subunit encoded by distinct
genes form Ca2 channels with di¡erent characteristics [2,3].
Among them, N- and P/Q-type channels are speci¢cally ex-
pressed in brain and play a crucial role in the regulation of
neurotransmitter release [4]. Various speci¢c ligands have
been used to distinguish Ca2 channel subtypes pharmacolog-
ically, including g-conotoxins isolated from the venom of
marine Conus snails. g-Conotoxin GVIA and MVIIA specif-
ically block N-type Ca2 channel activity [4]. In contrast, g-
conotoxin MVIIC preferentially inhibits the P/Q-type Ca2
channel, however, it also inhibits N-type Ca2 channels at
about 50-fold higher concentrations [4]. MVIIC and MVIIA
are about 70% identical to each other in amino acid sequence
(Fig. 1). Based on the results obtained with chimeric analogs
of MVIIA and MVIIC, residues in the second loop between
Cys8 and Cys15 have been shown to be important for binding
to N-type Ca2 channels [5^7]. Moreover, replacement of
Thr11 of MVIIC by Ala resulted in a loss of a⁄nity for N-
type Ca2 channels [8]. In the present study, we synthesized
analogs of MVIIC in which Thr11 was replaced with amino-
butyric acid (Abu), Asp, Asn, Leu, Phe, Ser, Thr, Tyr, or Val
(Fig. 1) in an attempt to obtain a selective P/Q-type Ca2
channel blocker, and tested their ability to bind to membranes
from rat cerebellum or baby hamster kidney (BHK) cells ex-
pressing N-type Ca2 channel, and inhibit Ba2 currents in
BHK cells.
2. Materials and methods
2.1. Materials
Reagents and chemicals were obtained as follows: fetal bovine se-
rum and geneticin, Gibco-BRL, Life Technology (Rockville, MD,
USA); methotrexate, Sigma (St. Louis, MO, USA); streptomycin
and penicillin, Meiji Seika (Tokyo, Japan); [125I]GVIA and
[125I]MVIIC, NEN (Boston, MA, USA); tetrodotoxin, Wako (Osaka,
Japan).
2.2. Cell culture
BHK cells expressing K1B and L1A subunits from rabbit brain and
K2/N subunit from rabbit skeletal muscle that formed N-type Ca2
channels (BHKN101) were grown in Dulbecco’s modi¢ed Eagle’s me-
dium containing 5% fetal calf serum, streptomycin (600 Wg/ml), pen-
icillin (30 U/ml), geneticin (600 Wg/ml) and methotrexate (0.25 WM) as
described [9].
2.3. Synthesis and puri¢cation of peptides
Solid phase peptide synthesis, amino acid analysis and puri¢cation
were performed as described previously [5,7,8,10]. Circular dichroism
spectra of all the analogs synthesized in this study were similar to that
of native MVIIC.
2.4. Binding assay
The binding activity to N- or P/Q-type Ca2 channels in rat cere-
bellar P2 membranes was determined by competition assay with
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[125I]GVIA or [125I]MVIIC as described [11]. P2 membranes of
BHKN101 cells were prepared according to the method of cerebellar
P2 membrane preparation [12]. Brie£y, cultured BHKN101 cells were
harvested with cell scraper, and centrifuged at 2000 rpm for 5 min.
Pellets were suspended with 10 mM Tris^HCl containing various pro-
tease inhibitors: 1 WM pepstatin A, 1 Wg/ml leupeptin, 1 Wg/ml anti-
pain, 1 mM 1,10-phenanthroline monohydrate, and 1 mM phenyl-
methylsulfonyl £uoride, and sonicated. After centrifugation (2000
rpm for 5 min), the supernatant was recovered and spun at
10 000Ug for 15 min. Protein was assayed by the Bradford method
using an IgG standard. P2 membranes of BHKN101 cells were incu-
bated with [125I]GVIA (0.5 nM) for 1.5 h on ice or at 25‡C, and
membrane-bound radioactivity was measured as described [11].
2.5. Electrophysiology
Whole-cell voltage-clamp recording [13] was performed using an
Axopatch 1B ampli¢er (Axon Instruments, Foster, CA, USA). Patch
electrodes with a tip resistance of 2^5 M6 were used. Cells were held
at 370 mV, then activated by a depolarization pulse at +10 mV (150
ms) preceding hyperpolarization pulse at 390 mV (20 ms), and re-
corded membrane currents were stored after A/D converting with
Digidata 1200 (Axon Instruments, Foster, CA, USA). Results were
analyzed with pClamp version 6.0 (Axon Instruments, Foster, CA,
USA). The patch pipette solution contained (in mM): CsCl 120,
TEA-Cl 20, EGTA-Cs 10, ATP-Mg 3, GTP 0.2, and HEPES-Cs 10.
The bath solution contained (in mM): NaCl 135, BaCl2 10, CsCl 5.5,
MgCl2 2, HEPES-Na 10, and tetrodotoxin 0.001. Both solutions were
adjusted at pH 7.2 by CsOH or NaOH, respectively. All experiments
were performed at room temperature.
3. Results
In rat cerebellar P2 membranes, MVIIA selectively bound
to N-type Ca2 channel (Fig. 2). The binding of [125I]GVIA
was inhibited with MVIIA at low concentrations
(IC50 = 4.0U10310 M), but the binding of [125I]MVIIC was
not (IC50s 1036 M). In contrast, MVIIC competed with
the binding of [125I]MVIIC at low concentrations
(IC50 = 3.0U1039 M), but a 20 times higher concentration
was required to compete with [125I]GVIA binding
(IC50 = 6.5U1038 M), thus MVIIC displayed low speci¢city
(Fig. 2).
Previously, we found that T11A-MVIIC lost binding activ-
ity for N-type Ca2 channels (IC50s 1036 M), and only
retained weak a⁄nity for P/Q-type Ca2 channels
(IC50 = 1.7U1036 M) [8]. We therefore synthesized a series
of mutants by replacing Thr11 with various amino acids
(Fig. 2, open circles). T11L showed a 30-fold increase in af-
¢nity for N-type Ca2 channels (IC50 = 2.2U1039 M), and a
10-fold decrease in a⁄nity for P/Q-type Ca2 channel
(IC50 = 3.3U1038 M), indicating improved speci¢city for N-
type Ca2 channels. On the other hand, T11V, T11Abu,
T11N, T11S had varying a⁄nities for N-type channels, but
their a⁄nity for P/Q-type channel was almost the same as
T11L. The IC50 values of T11V, T11Abu, and T11N for the
N-type channel were 3.2U1038 M, 3.7U1038 M, and
1.0U1036 M, respectively. T11S lost a⁄nity for the N-type
channel. T11D, T11F and T11Y displayed a signi¢cant de-
crease in a⁄nity for both types of Ca2 channel
(IC50s 1036 M). These results further indicate that the amino
acid at the 11th position is important for the selective binding
to N- and P/Q-type Ca2 channel. T11S showed marked de-
crease in a⁄nity for N-type Ca2 channel, but retained a⁄n-
ity for P/Q-type Ca2 channels. Thus, we considered T11S to
be an analog of MVIIC that is selective for P/Q-type Ca2
channels.
Because binding assays do not directly re£ect channel
blockade, we used the patch-clamp technique to examine the
ability of analogs to inhibit Ba2 currents in BHKN101 cells
expressing N-type Ca2 channel genes. Surprisingly however,
as shown in Fig. 3, there was essentially no di¡erence in the
inhibition of Ba2 currents in BHKN101 cells between
MVIIA, MVIIC and T11S, with IC50 values of 5.7U1039
Fig. 1. Amino acid sequences and disul¢de bonds of g-conotoxin
MVIIA, MVIIC and T11X-MVIIC.
Fig. 2. Inhibition by MVIIC analogs of [125I]GVIA or [125I]MVIIC
binding to rat cerebellar P2 membrane fraction. Closed circles indi-
cate the IC50 value of native MVIIA and MVIIC, respectively.
Open circles indicate the IC50 values of Thr11 mutants of MVIIC.
The substituted amino acids are indicated in the circles.
Fig. 3. Inhibition by MVIIA, MVIIC and their analogs, T11S and
T11A of Ba2 currents in BHKN101 cells. All experiments were
performed in the whole-cell patch con¢guration. Cells were held at
370 mV, then activated by a depolarizing pulse to +10 mV (150
ms) preceding a hyperpolarizing pulse to 390 mV (20 ms). Cono-
toxins were applied to the bath. Results are expressed as means
þ S.E.M. The inhibition by T11A at 1038 M was the only signi¢-
cant di¡erence from other conotoxins at the same concentration us-
ing Student’s t test for unpaired data (P6 0.05).
FEBS 24629 19-2-01
K. Minami et al./FEBS Letters 491 (2001) 127^130128
M, 6.9U1039 M, and 7.1U1039 M, respectively. T11A, which
lost binding activity for cerebellar P2 membranes, still showed
signi¢cant inhibitory action with only a slight decrease in
activity (IC50 = 6.0U1038 M).
To study whether the di¡erence came from cell prepara-
tions, binding assays were performed with BHKN101 cells,
and results compared with those obtained with cerebellar P2
membranes. Two experimental conditions were examined; (1)
identical conditions to binding assays with cerebellar P2 mem-
branes and (2) identical conditions to patch-clamp experi-
ments with BHKN101 cells. However, there was no signi¢cant
di¡erence of the a⁄nity of MVIIA, MVIIC and their analogs
in these conditions, except that T11A showed slightly de-
creased a⁄nity in the bath solution of electrophysiological
experiments (Fig. 4). In BHKN101 cells with hypotonic con-
ditions (10 mM Tris^HCl), the rank order of competition of
MVIIA, MVIIC and T11S with [125I]GVIA was the same as in
cerebellar P2 membranes, but the di¡erences were smaller. The
IC50 value of MVIIA (2.1U1039 M) was higher than in cer-
ebellar P2 membranes, whereas the values of MVIIC
(2.4U1038 M) and T11S (7.5U1038 M) were decreased.
4. Discussion
Previously, we reported that Thr11, Lys2 and Tyr13 of
MVIIC are essential for binding to the N-type Ca2 channel
[5,7,8]. Among these three residues, only the amino acid at the
11th position is not conserved between MVIIA and MVIIC,
and the binding activity of T11A-GVIA to the N-type Ca2
channel was retained [14,15]. So, we hypothesized that Thr11
is an important site for MVIIC binding to Ca2 channel. The
results in this study are consistent with this supposition. The
a⁄nity of T11L for N-type Ca2 channel was up to 1000-fold
higher than T11S in rat cerebellar P2 membranes, whereas the
a⁄nities for P/Q-type Ca2 channel were the same. With ana-
logs containing non-polar amino acids, the a⁄nities for N-
type Ca2 channel were related to methylene length
(LsV = AbusA). On the other hand, addition of a hydroxyl
group resulted in an increase in a⁄nity for P/Q-type Ca2
channel with the same length of side chains (TsAbu,
SsA). Hydroxyl groups are known to be important for the
selective binding to Ca2 channels, and in particular the hy-
droxyl group of Tyr13 is essential for the activity of g-con-
otoxins [10,14^17]. In contrast the basic amino acid, arginine,
is essential for interaction of W-conotoxins with Na channels
[18^20]. Binding of T11S to the N-type Ca2 channel was
extremely weak, while low a⁄nity binding to P/Q-type Ca2
channel was conserved. Therefore the modi¢cation of other
residues, in addition to the T11S mutation, will be required to
design a more potent P/Q-type Ca2 channel-speci¢c analog.
In our previous investigations, we used binding assays to
determine the activity of g-conotoxins [5,7,8,11,14,16]. In this
study, we measured Ba2 currents in BHKN101 cells express-
ing the class B K1 subunit of the N-type Ca2 channel using
the patch-clamp technique, revealing very similar dose-depen-
dent inhibition by MVIIA, MVIIC and T11S. It was not
however possible to examine the activity of g-conotoxins on
P/Q-type Ca2 channels using BHK cells expressing the class
A K1 subunit [21], as these cells displayed very low sensitivity
to both MVIIA and MVIIC (data not shown).
As the electrophysiological data were inconsistent with the
results of binding assays on cerebellar P2 membranes, binding
assays were performed using BHKN101 cell membranes. The
rank order of a⁄nity of the analogs was the same as that
observed for cerebellar P2 membranes, but the di¡erences in
a⁄nity were less marked. The a⁄nity of MVIIC was 11-fold
lower than MVIIA and 3-fold higher than T11S in BHKN101
cells, whereas in cerebellar P2 membranes a⁄nities di¡ered by
up to 100-fold. Moreover, when binding assays were carried
out with a bu¡er identical to the bath solution used in the
patch-clamp experiments, the results were not markedly di¡er-
ent, except that the IC50 value of T11A showed a slight right-
ward shift (Fig. 4B).
Two aspects of our data display discrepancies that merit
further discussion. Firstly di¡erences in the a⁄nities of g-con-
otoxin analogs for binding to native N-type channels in cer-
ebellar membranes versus heterologously expressed N-type
channels in BHK cells. Native tissues express splice variants
of Ca2 channel K1B subunit [2], which can also associate with
di¡erent L and K2/N subunits, and this variability may lead to
Fig. 4. Inhibition by MVIIA, MVIIC and their analogs, T11S and
T11A of [125I]GVIA binding to BHKN101 cell membranes. Symbols
were the same as Fig. 3. A: Experiments were done in hypotonic
conditions (10 mM Tris^HCl) on ice. B: Experiments were done in
isotonic conditions (bath solution of whole-cell patches) at room
temperature. Results are expressed as means þ S.E.M.
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di¡erences in pharmacological sensitivity. Satin et al. showed
that MVIIA-sensitive Ca2 currents in HIT-T15 cells were
MVIIC-insensitive [22]. In contrast Sanger et al. reported
Ba2 currents carried by rat N-type Ca2 channel in SCG
cells and HEK 293 cells that were blocked to similar extents
by MVIIA or MVIIC, although MVIIA inhibited electrical
contraction of smooth muscle more potently than MVIIC
[23]. Di¡erences in subunit composition may thus underlie
the discrepancies in binding activity between cerebellar P2
membranes and BHK cells expressing speci¢c K1B, K2/N and
L1 subunits. In brain, region-speci¢c expression of Ca2 chan-
nels with di¡erent sensitivity to g-conotoxins may occur, and
it may thus be possible to design region-speci¢c antagonists.
Secondly electrophysiological recording indicated very sim-
ilar IC50 values for MVIIA, MVIIC and T11S (Fig. 3) where-
as binding assays revealed clear di¡erences in a⁄nity. For
example MVIIC inhibited Ba2 currents by about 40% at
low concentrations (1039 M), but did not signi¢cantly displace
[125I]GVIA binding at the same concentration (Figs. 2 and
4B). This ¢nding is consistent with suggestions that N-type
Ca2 channels contain inhibitory binding sites for MVIIC
which are distinct from GVIA/MVIIA binding sites [24].
However attempts to directly measure the binding of
[125I]MVIIC to BHKN101 cells were not successful (data
not shown). Alternatively it is possible that discrepancies be-
tween patch-clamp and binding data may be related to di¡er-
ences in membrane potential. For electrophysiological record-
ing drugs are applied to cells that are voltage-clamped to 370
mV, while binding assays with broken cell membrane prepa-
rations are performed at 0 mV. Voltage-gated ion channels
undergo conformational changes in response to variations in
membrane potential which may in turn modulate g-conotoxin
binding a⁄nity. It is thus possible that di¡erences in the af-
¢nities of the analogs only become apparent at depolarized
membrane potentials.
Discussion in the preceding paragraphs is based on the
assumption that the discrepancy in the results comes from
the di¡erent nature of channels in native (but broken) mem-
branes, and a stable cell line heterologously expressing chan-
nels. We assume that this is the most probable explanation
and that BHKN101 cells are not an ideal system for this type
of study. However we should consider another possibility. It is
likely that T11S displays high a⁄nity, but dissociates much
more rapidly from N-type Ca2 channels than wild-type tox-
in. The electrophysiological data would thus re£ect the high
a⁄nity, but since the radioligand used in the binding assays,
[125I]GVIA, dissociates extremely slowly from its binding site,
the binding assay may have primarily tracked rapid dissocia-
tion of the T11S analog. If this explanation is correct, T11S is
not selective for P/Q-type Ca2 channels under equilibrium
conditions, but it could be a useful reagent since it constitutes
a readily reversible N-type channel antagonist. Further eval-
uation of the binding kinetics would be necessary to conclu-
sively answer this question.
In summary, on the basis of binding assays with cerebellar
P2 membranes, a P/Q-type Ca2 channel-selective analog of
MVIIC (T11S) was produced by replacing Thr11 with Ser.
A⁄nity may yet be improved by combining other substitu-
tions with T11S. As we recently developed combinatorial
methods for the synthesis of conotoxins [12], a variety of
analogs can now be synthesized concurrently. Although the
lack [125I]GVIA displacement indicated that T11S did not
interact with N-type channels, patch-clamp studies revealed
signi¢cant N-type channel blocking activity. These ¢ndings
illustrate the limitations of the design and evaluation of selec-
tive channel antagonists on the basis of binding assays alone.
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